{"id":59152,"date":"2026-03-10T13:48:32","date_gmt":"2026-03-10T05:48:32","guid":{"rendered":"https:\/\/flcube.com\/?p=59152"},"modified":"2026-03-10T13:48:33","modified_gmt":"2026-03-10T05:48:33","slug":"hutchmed-withdraws-tazverik-from-china-safety-concerns-drive-global-recall-of-epizyme-ipsen-ezh2-inhibitor","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59152","title":{"rendered":"HutchMed Withdraws TAZVERIK from China \u2013 Safety Concerns Drive Global Recall of Epizyme\/Ipsen EZH2 Inhibitor"},"content":{"rendered":"\n<p><strong>HutchMed (China) Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/HCM:NASDAQ\">NASDAQ: HCM<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/0013:HKG\">HKG: 0013<\/a>) announced <strong>immediate withdrawal and product recall<\/strong> of <strong>TAZVERIK (tazemetostat)<\/strong>, the <strong>EZH2 inhibitor<\/strong> licensed from <strong>Epizyme, Inc. (an Ipsen company)<\/strong>, from <strong>mainland China, Hong Kong, and Macau<\/strong>. The action follows <strong>Ipsen&#8217;s global safety-driven withdrawal<\/strong> after the <strong>Phase 1b\/3 SYMPHONY-1 trial<\/strong> in <strong>follicular lymphoma<\/strong> revealed <strong>secondary hematologic malignancies<\/strong> with risks outweighing potential benefits. HutchMed is <strong>discontinuing all active tazemetostat clinical trials<\/strong> and the <strong>NHSA has delisted<\/strong> the drug from <strong>provincial procurement platforms and the 2025 Innovative Drug List for Commercial Health Insurance effective immediately<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-withdrawal-overview\">Withdrawal Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>TAZVERIK (tazemetostat)<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>EZH2 (enhancer of zeste homolog 2) methyltransferase inhibitor<\/td><\/tr><tr><td><strong>Licensor<\/strong><\/td><td>Epizyme, Inc. (Ipsen subsidiary)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013)<\/td><\/tr><tr><td><strong>Markets Affected<\/strong><\/td><td>U.S. (Ipsen voluntary withdrawal), China (HutchMed recall), Hong Kong, Macau<\/td><\/tr><tr><td><strong>Indications Withdrawn<\/strong><\/td><td>Follicular lymphoma (FL), epithelioid sarcoma (ES)<\/td><\/tr><tr><td><strong>Trigger<\/strong><\/td><td>SYMPHONY-1 trial safety signal (secondary hematologic malignancies)<\/td><\/tr><tr><td><strong>Effective Date<\/strong><\/td><td>9\u202fMar\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-safety-signal-amp-clinical-context\">Safety Signal &amp; Clinical Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Trial<\/th><th>Design<\/th><th>Safety Finding<\/th><th>Risk-Benefit Assessment<\/th><\/tr><\/thead><tbody><tr><td><strong>SYMPHONY-1<\/strong><\/td><td>Phase 1b\/3<\/td><td>Tazemetostat + lenalidomide + rituximab (R\u00b2) vs. R\u00b2<\/td><td>Secondary hematologic malignancies observed<\/td><\/tr><tr><td><strong>Conclusion<\/strong><\/td><td>\u2014<\/td><td>Risks outweigh potential benefits in follicular lymphoma<\/td><td>Ipsen initiated global withdrawal<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Mechanism Concern:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>EZH2 Inhibition:<\/strong> Epigenetic modulation may disrupt hematopoietic stem cell regulation<\/li>\n\n\n\n<li><strong>Combination Risk:<\/strong> Tazemetostat + immunomodulatory (lenalidomide) + anti-CD20 potentially synergistic for myelosuppression\/malignancy<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-amp-commercial-actions\">Regulatory &amp; Commercial Actions<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Jurisdiction<\/th><th>Action<\/th><th>Authority<\/th><\/tr><\/thead><tbody><tr><td><strong>United States<\/strong><\/td><td>Voluntary withdrawal<\/td><td>Ipsen (manufacturer)<\/td><\/tr><tr><td><strong>China Mainland<\/strong><\/td><td>Product recall + trial discontinuation<\/td><td>HutchMed + NMPA coordination<\/td><\/tr><tr><td><strong>Hong Kong\/Macao<\/strong><\/td><td>Product recall<\/td><td>HutchMed<\/td><\/tr><tr><td><strong>Procurement<\/strong><\/td><td>Delisting from all provincial platforms<\/td><td>NHSA (National Healthcare Security Administration)<\/td><\/tr><tr><td><strong>Insurance<\/strong><\/td><td>Removal from 2025 Innovative Drug List for Commercial Health Insurance<\/td><td>NHSA (per enterprise application)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Financial Impact:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HutchMed Revenue:<\/strong> TAZVERIK China sales immaterial to 2025 consolidated revenue ($548.5M total); minimal P&amp;L impact<\/li>\n\n\n\n<li><strong>Ipsen Write-down:<\/strong> Potential impairment on Epizyme acquisition ($247M in 2022)<\/li>\n\n\n\n<li><strong>Clinical Trial Costs:<\/strong> HutchMed trial discontinuation costs anticipated Q1 2026<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>HutchMed Pipeline<\/strong><\/td><td>Loss of licensed oncology asset; reinforces strategy pivot to internal discovery (sovleplenib, fruquintinib)<\/td><\/tr><tr><td><strong>China Regulatory Speed<\/strong><\/td><td>NHSA same-day delisting demonstrates post-approval pharmacovigilance responsiveness<\/td><\/tr><tr><td><strong>Epizyme\/Ipsen Portfolio<\/strong><\/td><td>EZH2 inhibitor class setback; raises questions about epigenetic therapy safety profile<\/td><\/tr><tr><td><strong>Investor Sentiment<\/strong><\/td><td>HCM shares may face short-term pressure on pipeline risk perception; mitigated by limited revenue exposure<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-forward-looking-considerations\">Forward-Looking Considerations<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HutchMed Response:<\/strong> Focus resources on internal pipeline assets (HSK31858, sovleplenib) and partnered programs with stronger safety profiles<\/li>\n\n\n\n<li><strong>Class Effect:<\/strong> FDA\/EMA may review other EZH2 inhibitors (valemetostat) for similar safety signals<\/li>\n\n\n\n<li><strong>Lessons Learned:<\/strong> Importance of long-term safety monitoring in epigenetic modulators; combination trial design risk assessment<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding safety profile implications, regulatory responses, and strategic adjustments following the TAZVERIK withdrawal. Actual results may differ due to ongoing safety investigations, regulatory inquiries, and competitive dynamics in the oncology market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026030900615_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026030900615_c.\"><\/object><a id=\"wp-block-file--media-9107629e-89cb-49eb-8b87-64533627f7b9\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026030900615_c.pdf\">2026030900615_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026030900615_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-9107629e-89cb-49eb-8b87-64533627f7b9\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced immediate withdrawal and product recall of TAZVERIK&#8230;<\/p>\n","protected":false},"author":1,"featured_media":59155,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[1105,285,1104,67],"class_list":["post-59152","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-hkg-0013","tag-hutchmed","tag-nasdaq-hcm","tag-nhsa-prev-smia"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>HutchMed Withdraws TAZVERIK from China \u2013 Safety Concerns Drive Global Recall of Epizyme\/Ipsen EZH2 Inhibitor - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced immediate withdrawal and product recall of TAZVERIK (tazemetostat), the EZH2 inhibitor licensed from Epizyme, Inc. (an Ipsen company), from mainland China, Hong Kong, and Macau. The action follows Ipsen&#039;s global safety-driven withdrawal after the Phase 1b\/3 SYMPHONY-1 trial in follicular lymphoma revealed secondary hematologic malignancies with risks outweighing potential benefits. HutchMed is discontinuing all active tazemetostat clinical trials and the NHSA has delisted the drug from provincial procurement platforms and the 2025 Innovative Drug List for Commercial Health Insurance effective immediately.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59152\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HutchMed Withdraws TAZVERIK from China \u2013 Safety Concerns Drive Global Recall of Epizyme\/Ipsen EZH2 Inhibitor\" \/>\n<meta property=\"og:description\" content=\"HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced immediate withdrawal and product recall of TAZVERIK (tazemetostat), the EZH2 inhibitor licensed from Epizyme, Inc. (an Ipsen company), from mainland China, Hong Kong, and Macau. The action follows Ipsen&#039;s global safety-driven withdrawal after the Phase 1b\/3 SYMPHONY-1 trial in follicular lymphoma revealed secondary hematologic malignancies with risks outweighing potential benefits. HutchMed is discontinuing all active tazemetostat clinical trials and the NHSA has delisted the drug from provincial procurement platforms and the 2025 Innovative Drug List for Commercial Health Insurance effective immediately.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59152\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-10T05:48:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-10T05:48:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1002.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59152#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59152\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"HutchMed Withdraws TAZVERIK from China \u2013 Safety Concerns Drive Global Recall of Epizyme\\\/Ipsen EZH2 Inhibitor\",\"datePublished\":\"2026-03-10T05:48:32+00:00\",\"dateModified\":\"2026-03-10T05:48:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59152\"},\"wordCount\":465,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59152#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1002.webp\",\"keywords\":[\"HKG: 0013\",\"HutchMed\",\"NASDAQ: HCM\",\"NHSA (prev. SMIA)\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59152#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59152\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59152\",\"name\":\"HutchMed Withdraws TAZVERIK from China \u2013 Safety Concerns Drive Global Recall of Epizyme\\\/Ipsen EZH2 Inhibitor - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59152#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59152#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1002.webp\",\"datePublished\":\"2026-03-10T05:48:32+00:00\",\"dateModified\":\"2026-03-10T05:48:33+00:00\",\"description\":\"HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced immediate withdrawal and product recall of TAZVERIK (tazemetostat), the EZH2 inhibitor licensed from Epizyme, Inc. (an Ipsen company), from mainland China, Hong Kong, and Macau. The action follows Ipsen's global safety-driven withdrawal after the Phase 1b\\\/3 SYMPHONY-1 trial in follicular lymphoma revealed secondary hematologic malignancies with risks outweighing potential benefits. HutchMed is discontinuing all active tazemetostat clinical trials and the NHSA has delisted the drug from provincial procurement platforms and the 2025 Innovative Drug List for Commercial Health Insurance effective immediately.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59152#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59152\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59152#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1002.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1002.webp\",\"width\":1080,\"height\":608,\"caption\":\"HutchMed Withdraws TAZVERIK from China \u2013 Safety Concerns Drive Global Recall of Epizyme\\\/Ipsen EZH2 Inhibitor\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59152#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HutchMed Withdraws TAZVERIK from China \u2013 Safety Concerns Drive Global Recall of Epizyme\\\/Ipsen EZH2 Inhibitor\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"HutchMed Withdraws TAZVERIK from China \u2013 Safety Concerns Drive Global Recall of Epizyme\/Ipsen EZH2 Inhibitor - Insight, China&#039;s Pharmaceutical Industry","description":"HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced immediate withdrawal and product recall of TAZVERIK (tazemetostat), the EZH2 inhibitor licensed from Epizyme, Inc. (an Ipsen company), from mainland China, Hong Kong, and Macau. The action follows Ipsen's global safety-driven withdrawal after the Phase 1b\/3 SYMPHONY-1 trial in follicular lymphoma revealed secondary hematologic malignancies with risks outweighing potential benefits. HutchMed is discontinuing all active tazemetostat clinical trials and the NHSA has delisted the drug from provincial procurement platforms and the 2025 Innovative Drug List for Commercial Health Insurance effective immediately.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59152","og_locale":"en_US","og_type":"article","og_title":"HutchMed Withdraws TAZVERIK from China \u2013 Safety Concerns Drive Global Recall of Epizyme\/Ipsen EZH2 Inhibitor","og_description":"HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced immediate withdrawal and product recall of TAZVERIK (tazemetostat), the EZH2 inhibitor licensed from Epizyme, Inc. (an Ipsen company), from mainland China, Hong Kong, and Macau. The action follows Ipsen's global safety-driven withdrawal after the Phase 1b\/3 SYMPHONY-1 trial in follicular lymphoma revealed secondary hematologic malignancies with risks outweighing potential benefits. HutchMed is discontinuing all active tazemetostat clinical trials and the NHSA has delisted the drug from provincial procurement platforms and the 2025 Innovative Drug List for Commercial Health Insurance effective immediately.","og_url":"https:\/\/flcube.com\/?p=59152","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-10T05:48:32+00:00","article_modified_time":"2026-03-10T05:48:33+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1002.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59152#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59152"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"HutchMed Withdraws TAZVERIK from China \u2013 Safety Concerns Drive Global Recall of Epizyme\/Ipsen EZH2 Inhibitor","datePublished":"2026-03-10T05:48:32+00:00","dateModified":"2026-03-10T05:48:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59152"},"wordCount":465,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=59152#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1002.webp","keywords":["HKG: 0013","HutchMed","NASDAQ: HCM","NHSA (prev. SMIA)"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59152#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59152","url":"https:\/\/flcube.com\/?p=59152","name":"HutchMed Withdraws TAZVERIK from China \u2013 Safety Concerns Drive Global Recall of Epizyme\/Ipsen EZH2 Inhibitor - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=59152#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=59152#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1002.webp","datePublished":"2026-03-10T05:48:32+00:00","dateModified":"2026-03-10T05:48:33+00:00","description":"HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced immediate withdrawal and product recall of TAZVERIK (tazemetostat), the EZH2 inhibitor licensed from Epizyme, Inc. (an Ipsen company), from mainland China, Hong Kong, and Macau. The action follows Ipsen's global safety-driven withdrawal after the Phase 1b\/3 SYMPHONY-1 trial in follicular lymphoma revealed secondary hematologic malignancies with risks outweighing potential benefits. HutchMed is discontinuing all active tazemetostat clinical trials and the NHSA has delisted the drug from provincial procurement platforms and the 2025 Innovative Drug List for Commercial Health Insurance effective immediately.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59152#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59152"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=59152#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1002.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1002.webp","width":1080,"height":608,"caption":"HutchMed Withdraws TAZVERIK from China \u2013 Safety Concerns Drive Global Recall of Epizyme\/Ipsen EZH2 Inhibitor"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59152#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"HutchMed Withdraws TAZVERIK from China \u2013 Safety Concerns Drive Global Recall of Epizyme\/Ipsen EZH2 Inhibitor"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1002.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59152","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59152"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59152\/revisions"}],"predecessor-version":[{"id":59157,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59152\/revisions\/59157"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/59155"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59152"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59152"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59152"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}